What is Prami?
Pramipexole (Prami) is a dopamine receptor agonist originally developed for the treatment of Parkinson's disease and restless legs syndrome. It works by binding to and activating dopamine receptors in the brain, compensating for low dopamine activity and restoring normal signaling in affected pathways. In the performance and hormone management space, pramipexole is used primarily as a prolactin management tool, particularly by those running 19-nor compounds or growth hormone secretagogues that tend to elevate prolactin. Many users prefer it over cabergoline due to concerns around cabergoline's potential cardiac effects, specifically its association with heart valve issues at higher doses. The benefits users experience are largely downstream of getting prolactin under control rather than direct effects of the drug itself.
Mechanisms of Action
Dopamine receptor agonism by binding to D2 and D3 dopamine receptors in the brain, directly stimulating dopaminergic activity and producing the downstream effects on motivation, mood, and motor regulation
Prolactin suppression via dopamine's inhibitory role on prolactin secretion from the pituitary gland, with D2 receptor activation in the tuberoinfundibular pathway reducing prolactin output effectively
Hypothalamic dopamine pathway modulation restoring dopaminergic tone in reward and motivation circuits, contributing to improved mood, drive, and sexual function as prolactin normalizes
Preferred cardiac safety profile vs cabergoline with pramipexole not carrying the same degree of concern around fibrotic heart valve changes that have been associated with cabergoline at higher chronic doses
Benefits
Prolactin control the primary reason for its use in performance contexts, addressing the elevated prolactin that commonly results from 19-nor compounds like trestolone, NPP, and trenbolone, or from growth hormone peptides
Improved motivation and drive as dopaminergic tone is restored and prolactin is brought back into range, with users reporting noticeably better mental energy and focus
Reduced breast sensitivity with gynecomastia-related nipple sensitivity often driven by elevated prolactin responding well to pramipexole-mediated suppression
Better erections and bedroom performance as high prolactin is a well-established driver of erectile dysfunction and sexual dysfunction, both of which tend to resolve as levels normalize
Less water retention with prolactin playing a role in fluid retention, its reduction often resulting in a leaner and drier appearance
More stable mood with the dopaminergic and prolactin-related improvements combining to produce a more even and positive emotional baseline during cycle
Dosing
Phase | Dose | Timing |
|---|---|---|
Starting | 0.25 mg | Before bed |
Working / Sweet Spot | 0.5 mg | Before bed |
Maximum | 1 mg | Before bed |
Maintenance dose | 0.25 mg | Before bed during intense cycle phases |
Always start at 0.25 mg before bed and titrate up slowly over multiple days. The nausea from jumping straight to a higher dose can be severe and will ruin your day if you are not careful. Dosing before bed helps to mitigate the nausea and dizziness side effects by sleeping through the peak. Use until prolactin-related issues have resolved, then taper to a maintenance dose or discontinue. Always have it on hand when running 19-nor compounds or growth hormone secretagogues.
Warning: Do not start at a high dose. Prami-induced nausea is severe and can be incapacitating if you jump the dose too fast. Titrate up slowly, always dose before bed, and give your body time to adjust at each step before increasing further.
Safety Profile
Nausea and dizziness the most commonly reported and practically significant side effects, strongly dose-dependent and largely avoidable by starting low and titrating slowly with bedtime dosing
Daytime sleepiness possible particularly when first starting or after dose increases, affecting alertness and concentration during the adjustment period
Orthostatic hypotension a drop in blood pressure upon standing that can cause lightheadedness, more common at higher doses or during the initiation phase
GI distress including stomach discomfort and digestive upset, again most prominent at higher doses and during the early titration phase
Impulse control disorders a rare but serious risk associated with dopamine agonists as a class, including compulsive behaviors; monitor for behavioral changes during prolonged use
Citations
Gribkoff, V. K., et al. Pramipexole and dopamine receptor agonism in neurological research. PubMed. https://pubmed.ncbi.nlm.nih.gov/10389840/
Disclaimer: The information provided is intended solely for educational purposes and should not be considered a replacement for professional medical advice. All compounds referenced are not for human consumption.
